KR20240078554A - Composition for improving inflammation or pruritis comprising an extract of Sikbangpung as an active ingredient - Google Patents

Abstract

The composition of the present invention is non-toxic and has the effect of preventing, improving or treating inflammation or skin itchiness as it contains the natural product, Sikbangpung extract, as an active ingredient, and is used as a cosmetic composition; food composition; feed composition; It can be usefully used as a pharmaceutical composition or quasi-drug composition.

Description

Composition for improving inflammation or pruritis comprising an extract of Sikbangpung as an active ingredient}

The present invention relates to a composition for improving inflammation or skin itchiness, comprising extract of Siberia fernata as an active ingredient.

Some of the substances that play an important role in the process of maintaining homeostasis of living organisms are physiologically active substances derived from various living organisms. To date, much research has been conducted on numerous biologically active substances, and among them, research on biologically active substances isolated from microorganisms, plants, or animals is a very important area in the fields of life science and medicine.

Meanwhile, the inflammatory response involves various inflammatory mediators and immune cells in local blood vessels and body fluids when cells or tissues are damaged or infected with external infectious agents such as bacteria, mold, viruses, and various types of allergens, resulting in enzyme activation, It shows a series of complex physiological reactions such as secretion of inflammatory mediators, fluid infiltration, cell migration, and tissue destruction, as well as external symptoms such as erythema, edema, fever, and pain. The normal inflammatory response removes external infectious agents and regenerates damaged tissues to restore the function of the organism, but if the inflammatory response occurs excessively or continuously due to antigens not being removed or internal substances as the cause, it actually promotes mucosal damage, resulting in damage to the mucous membrane. In some cases, it leads to diseases such as cancer.

It is known that various biochemical phenomena are involved in causing inflammation, especially nitric oxide synthase (NOS), an enzyme that generates nitric oxide (NO), and enzymes related to the biosynthesis of prostaglandins. It is known to play the most important role in mediating inflammatory responses. Therefore, blocking inflammation is achieved by inhibiting the activity of nitric oxide synthase (NOS), an enzyme that generates nitric oxide from L-arginine, and cyclooxygenase (COX), an enzyme involved in synthesizing prostaglandins from arachidonic acid. The goal is to develop a treatment.

Meanwhile, atopic dermatitis is a chronically recurrent itchy dermatitis that commonly occurs in infants and young children and is accompanied by itching, dry skin, or characteristic eczema in patients or family members. Typical symptoms of atopic dermatitis appear on the hands, scalp, face, neck, elbows, and knees. The skin becomes very dry, itchy and inflamed, and peels off like scales. When scratched hard, the skin thickens and wrinkles deeply.

The cause of atopic dermatitis has not yet been clearly identified, but it includes an abnormal increase in IgE, a decrease in the number and function of T cells, which play a central role in cellular immunity, infiltration of monocytes and macrophages, an increase in mast cells and eosinophils, and CD4+. Immunological factors such as an increase in T lymphocytes have been reported (J Invest Dermatol., 96:523-526, 1991; J Invest Dermatol., 97:389-394, 1991; Immunol., 11:81-88, 1999; Curr Drug Targets Inflamm Allergy., 2:199-120, 2003; J. Adv Immunol., 78:57, 2001; -773, 2002; Pediatr Allergy Immunol., 19:605-613, 2008).

Currently, steroid drugs that suppress inflammatory reactions and cytokine production are mainly used as treatments for atopic dermatitis, but long-term administration causes various side effects such as skin atrophy and the possibility of growth retardation, so the use of non-steroid drugs is increasing recently. there is. However, non-steroid drugs also have various side effects, such as symptoms such as erythema, itching, edema, maceration, and lichenification, and weakened immunity, making it difficult to treat the underlying atopic dermatitis. Therefore, research is needed to find substances with excellent therapeutic effects from natural products with relatively high safety. Above all, natural materials that are safe for the living body, have stable active ingredients, and are more effective than existing substances that improve inflammation and skin itching. development is urgently needed.

Republic of Korea Patent No. 10-1803757

The present invention aims to solve the above-described problems and other problems associated therewith.

An exemplary object of the present invention is to provide a cosmetic composition for preventing or improving inflammation or skin itchiness, comprising an extract of Sikbangpung as an active ingredient; food composition; To provide a feed composition.

Another exemplary object of the present invention is to provide a pharmaceutical composition for preventing or treating inflammation or skin itchiness, comprising an extract of Siberia falciparum as an active ingredient; The purpose is to provide a quasi-drug composition.

Another exemplary object of the present invention is to prepare a mixture by adding a solvent to (a) Sikbangpung; and (b) extracting the mixture of step (a) by subjecting it to ultrasonic waves.

The technical problem to be achieved according to the technical idea of the invention disclosed in this specification is not limited to the problem to solve the problems mentioned above, and other problems not mentioned can be clearly understood by those skilled in the art from the description below. There will be.

This is explained in detail as follows. Meanwhile, each description and embodiment disclosed in this application may also be applied to each other description and embodiment. That is, all combinations of the various elements disclosed in this application fall within the scope of this application. Additionally, the scope of the present application cannot be considered limited by the specific description described below.

In one aspect for achieving the above object, the present invention provides a cosmetic composition for preventing or improving inflammation or skin itchiness, which contains an extract of Sikbangpung as an active ingredient.

"Sikbangpung" of the present invention refers to the roots of Peucedanum japoincum, which is a three-year-old herbaceous plant belonging to the genus Apiaceae and oilseed herbs, and its habitat is a humid, sunny sandy beach in southern Korea. Or rock crevices, Japan, Taiwan, China, the Philippines, etc.

The term "extract" in the present invention refers to the extract itself, such as an extract obtained by extraction treatment of Sikbangpung, a diluted or concentrated liquid of the extract, a dried product obtained by drying the extract, a crude product or purified product of the extract, or a mixture thereof, etc. and extracts of all formulations that can be formed using the extract.

In the present invention, the extract may be used from any one or two or more parts selected from the leaves, stems, fruits, roots, bark and seeds of Sikbangpung, but is not limited thereto.

In the present invention, the extraction is not particularly limited and can be extracted according to methods commonly used in the art. Non-limiting examples of the extraction method include hot water extraction, cold immersion extraction, solvent extraction, steam distillation, elution, compression, ultrasonic extraction, filtration, and reflux extraction, which are performed alone or using a combination of two or more methods. It can be performed by doing this.

The extract of the present invention is extracted from Sikbangpung using an appropriate solvent, and may include, for example, a crude extract, a polar solvent-soluble extract, or a non-polar solvent-soluble extract. The type of extraction solvent used to prepare the extract is not particularly limited, and any solvent known in the art can be used. Non-limiting examples of the extraction solvent include water; lower alcohols having 1 to 4 carbon atoms such as methanol, ethanol, propanol, isopropanol, butanol, propyl alcohol, and butyl alcohol; Polyhydric alcohols such as glycerin, butylene glycol, and propylene glycol; Hydrocarbon solvents such as methyl acetate, ethyl acetate, acetone, benzene, hexane, diethyl ether, and dichloromethane;　Or a mixture thereof can be used. Specifically, the extraction solvent may be ethanol. Additionally, a solvent extract can be prepared by extracting the extract one or more times using the solvent.

In the present invention, the term “active ingredient” refers to an ingredient that exhibits the desired activity alone or can exhibit activity in combination with a carrier that is not active on its own.

The term "prevention" in the present invention refers to any action that suppresses or delays symptoms caused by an inflammatory response or skin itching in an individual by administering a composition containing the extract of P. fernata according to the present invention.

The term "improvement" in the present invention refers to any action that improves or benefits the inflammatory response or skin itching condition of an individual by administering a composition containing the extract of the present invention.

The cosmetic composition according to the present invention may contain a carrier acceptable in cosmetic formulations. Here, “acceptable carrier in cosmetic preparations” refers to compounds or compositions already known and used that can be included in cosmetic preparations, or compounds or compositions to be developed in the future, which exhibit toxicity, instability or irritation beyond what the human body can adapt to upon contact with the skin. It says there is no such thing. The carrier may be included in the cosmetic composition of the present invention in an amount of about 1% by weight to about 99.99% by weight based on the total weight, preferably about 90% by weight to about 99.99% by weight of the weight of the composition. However, since the ratio varies depending on the formulation in which the cosmetic composition of the present invention is manufactured, its specific application area (face, neck, etc.), and its preferred application amount, the ratio limits the scope of the present invention in any respect. It should not be understood as doing so.

Examples of the carrier include alcohol, oil, surfactant, fatty acid, silicone oil, wetting agent, humectant, viscosity modifier, emulsion, stabilizer, ultraviolet scattering agent, ultraviolet absorber, coloring agent, fragrance, etc. Compounds or compositions that can be used as alcohols, oils, surfactants, fatty acids, silicone oils, wetting agents, moisturizers, viscosity modifiers, emulsions, stabilizers, UV scattering agents, UV absorbers, coloring agents, and fragrances are already known in the art. Therefore, a person skilled in the art can select and use an appropriate material or composition.

The cosmetic composition according to the present invention can be manufactured in various forms, such as lotion, essence, gel, emulsion, lotion, cream (oil-in-water type, water-in-oil type, multi-phase), solution, suspension (anhydrous and aqueous), It can be manufactured in the form of anhydrous products (oil and glycol-based), gels, masks, packs, powders, or capsules (soft capsules, hard capsules) with a coating such as gelatin.

In addition, suitable cosmetic formulations include, for example, solutions, gels, solid or pasty anhydrous products, emulsions obtained by dispersing the oil phase in the water phase, suspensions, microemulsions, microcapsules, microgranules or ionic (liposomes), non-ionic. It may be provided in the form of a vesicular dispersant, cream, skin, lotion, powder, ointment, spray or stick. Additionally, it can be prepared in the form of foam or in the form of an aerosol composition further containing compressed propellant.

In addition, the cosmetic composition of the present invention further contains fatty substances, organic solvents, solubilizers, thickening and gelling agents, softeners, antioxidants, suspending agents, stabilizers, foaming agents, fragrances, surfactants, water, ionic type. or non-ionic emulsifiers, fillers, sequestering and chelating agents, preservatives, vitamins, blocking agents, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic active agents, lipid vesicles or any commonly used in cosmetics. It may contain auxiliaries commonly used in the fields of cosmetology or dermatology, such as other ingredients. Additionally, the above ingredients can be introduced in amounts commonly used in the field of dermatology.

In the present invention, skin includes not only the face, but also the scalp and the entire body. Cosmetic compositions that can be applied to the scalp include shampoos, rinses, treatments, hair growth agents, etc., and body cleansers that can be applied to the entire body. It can be manufactured in various forms for various purposes.

Accordingly, the cosmetic composition according to the present invention includes cosmetic forms for preventing or improving inflammation or skin itching.

In the present invention, inflammation refers to an inflammatory response in the body, and this inflammatory response may develop into an inflammatory disease accompanied by various symptoms, and prevention or improvement of the inflammation usually means “anti-inflammatory.”

The skin itching is a type of inflammatory disease and may be any one selected from atopic dermatitis, allergic dermatitis, urticaria, and contact dermatitis, but is not limited thereto.

In another aspect for achieving the above object, the present invention provides a food composition for preventing or improving inflammation or skin itchiness, which contains an extract of the anthurium ginseng as an active ingredient. “Sikbangpung”, “extract”, “active ingredient”, “inflammation”, “skin itching”, “prevention” and “improvement” of the present invention are as described above.

The food composition of the present invention may additionally contain, in addition to the extract of Siberian spp., any compound or natural extract whose safety has already been verified in the art and which is known to have the corresponding activity in order to improve the convenience of taking or ingesting. .

These compounds or extracts include compounds, extracts, and medicinal products listed in compendiums such as the Pharmacopoeia of each country ('Korean Pharmacopoeia' in Korea) and the Code of Health Functional Foods of each country ('Standards and Specifications for Health Functional Foods' notified by the Ministry of Food and Drug Safety in Korea). The laws of each country governing the manufacture and sale of compounds, extracts, and health functional foods that have received product approval in accordance with the laws of each country (the “Pharmaceutical Affairs Act” in Korea) (the “Act on Health Functional Foods” in Korea). Accordingly, compounds or extracts with recognized functionality may be included.

The term "food" in the present invention refers to meat, sausages, bread, chocolate, candies, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, beverages, tea, drinks, alcoholic beverages, There are vitamin complexes, nutritional supplements, functional foods, food additives, health functional foods, and health foods, and include all foods in the conventional sense.

The above-mentioned health food refers to food that has a more active health maintenance or promotion effect compared to general food, and health supplement food refers to food for the purpose of health supplementation. In some cases, the terms health functional food, health food, and health supplement are used interchangeably.

The term "health functional food" in the present invention is the same term as food for special health use (FoSHU), and refers to food with high medical and medical effects that has been processed to efficiently exhibit bioregulatory functions in addition to nutritional supply. it means. Here, “function” means adjusting nutrients to the structure and function of the human body or obtaining useful effects for health purposes, such as physiological effects. The food of the present invention can be manufactured by methods commonly used in the industry, and can be manufactured by adding raw materials and ingredients commonly added in the industry. Additionally, the food formulation can be manufactured without limitation as long as it is a formulation recognized as a food. The food composition of the present invention can be manufactured in various types of dosage forms, and unlike general drugs, it has the advantage of being made from food as a raw material and has no side effects that may occur when taking the drug for a long period of time, is excellent in portability, and is a food composition of the present invention. It can be taken as an adjuvant to improve or prevent inflammatory diseases.

Specifically, the above-mentioned health functional food is a food made by adding the extract of Siberian fern to food materials such as beverages, teas, spices, gum, and confectionery, or manufactured into pills, tablets, capsules, powders, suspensions, etc., and consuming it may cause health problems. It means that it brings about a specific effect, but unlike general drugs, it has the advantage of not having any side effects that may occur when taking the drug for a long time because it is made from food.

The food composition of the present invention is very useful because it can be consumed on a daily basis and can be expected to prevent or improve inflammation or skin itchiness.

The food composition of the present invention can be manufactured in any form, for example, beverages such as tea, juice, carbonated beverages, and electrolyte drinks, processed oils such as milk and yogurt, gums, rice cakes, Korean snacks, bread, It can be manufactured into foods such as snacks and noodles, and preparations such as tablets, capsules, pills, granules, liquids, powders, flakes, pastes, syrups, gels, jellies, bars, etc. In addition, the food composition of the present invention may have any product classification in terms of legal and functional classification as long as it complies with the enforcement laws and regulations at the time of manufacture and distribution. For example, it is a health functional food according to Korea's 'Act on Health Functional Foods', or confectionery, tea, beverages, and special food according to each food type according to the food code of Korea's 'Food Sanitation Act' (Ministry of Food and Drug Safety Notification 'Food Standards and Specifications'). It may be food for use, etc.

Additionally, the food composition of the present invention may contain food additives in addition to the active ingredients. Food additives can generally be understood as substances that are added to, mixed with, or infiltrated into food when manufacturing, processing, or preserving food. Since they are consumed daily and for a long period of time with food, their safety must be guaranteed. These food additives are classified into sweeteners, flavor enhancers, preservatives, emulsifiers, flavorings, etc. in terms of use.

The sweetener is used to impart an appropriate sweetness to food, and can be either natural or synthetic. For example, sweeteners such as neotame, lactitol, D-ribose, mannitol, D-maltitol, and sodium saccharin can be used.

The flavor enhancer is a food additive that enhances the taste or aroma of food, and both natural and synthetic agents can be used. For example, flavor enhancers may include disodium 5'-guanylate, L-glutamic acid, glycine, betaine, etc.

As the preservative, sodium metabisulfite, sulfurous anhydride, sorbic acid, benzoic acid, grapefruit seed extract, etc. may be used.

The emulsifier is a food additive that homogeneously mixes or maintains two or more immiscible phases such as water and oil, and may include sodium gluconate, glycerin fatty acid ester, lecithin, magnesium stearate, alginic acid, etc.

The flavoring agent is a food additive that gives a unique flavor to food or reinforces the original flavor of food lost during the manufacturing process. Ethyl vanillin, ethyl octanoate, linalyl acetate, allyl caproate, paramethylacetophenone, etc. may be used. .

In addition to the food additives described above, the food composition of the present invention may contain bioactive substances or minerals known in the art and whose safety is guaranteed as food additives for the purpose of supplementing and reinforcing functionality and nutrition. The bioactive substances include catechins contained in green tea, vitamins such as vitamin B1, vitamin C, vitamin E, and vitamin B12, tocopherol, and dibenzoylthiamine. Minerals include calcium preparations such as calcium citrate and stearic acid. Magnesium preparations such as magnesium, iron preparations such as iron citrate, chromium chloride, potassium iodide, selenium, germanium, vanadium, zinc, etc. are included.

The food composition of the present invention may contain the above-described food additives in an appropriate amount to achieve the purpose depending on the product type, and with respect to other food additives that may be included in the food composition of the present invention, each country's food code or You can refer to the Food Additives Code.

When using the Sikbangpung extract as a food additive, the Sikbangpung extract can be added as is or used together with other foods or food ingredients, and can be used appropriately according to conventional methods. The mixing amount of the active ingredient can be appropriately determined depending on the purpose of use.

In another aspect for achieving the above object, the present invention provides a feed composition for preventing or improving inflammation or skin itching, comprising an extract of the anthurium vulgaris as an active ingredient. “Sikbangpung”, “extract”, “active ingredient”, “inflammation”, “skin itching”, “prevention” and “improvement” of the present invention are as described above.

In the present invention, the term "feed" may mean any natural or artificial diet, meal, etc., or a component of the meal, for or suitable for eating, ingestion, and digestion by animals.

In the present invention, the feed composition may be formulated in the form of a normal feed and may include known feed ingredients. It can also be used as a feed additive, which is added to the feed used in the form of an additive. The feed additive of the present invention corresponds to supplementary feed under the Feed Management Act, and includes mineral preparations such as sodium bicarbonate (sodium bicarbonate), bentonite, magnesium oxide, and complex minerals, and trace minerals such as zinc, copper, cobalt, and selenium. preparations, vitamin preparations such as kerotene, vitamin E, vitamin A, D, nicotinic acid, and vitamin B complex, protective amino acid preparations such as methionine and lysic acid, protective fatty acid preparations such as fatty acid calcium salts, probiotics (lactic acid bacteria), yeast culture, Live bacteria such as mold fermentation products, yeast agents, etc. may be additionally included.

The feed or feed additive of the present invention can be applied to a number of animal diets, including mammals, poultry, and fish.

In another aspect for achieving the above object, the present invention provides a pharmaceutical composition for preventing or treating inflammation or itching of the skin, which contains an extract of the anthurium vulgaris as an active ingredient. “Sikbangpung”, “extract”, “active ingredient”, “inflammation”, “skin itching” and “prevention” of the present invention are as described above.

The term "treatment" of the present invention refers to any action that improves, alleviates, or benefits an individual's symptoms of inflammation or skin itching by administering a composition containing the extract of P. fragrantia vulgaris or the like according to the present invention.

The pharmaceutical composition of the present invention may further include a pharmaceutically acceptable carrier, excipient, or diluent according to a conventional method. Pharmaceutically acceptable carriers are well known in the art depending on the administration route or dosage form, and for specifics, each country's pharmacopoeia, including the 'Korean Pharmacopoeia', can be referred to. Carriers, excipients and diluents that may be included in the composition of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, Examples include, but are not limited to, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil. Additionally, carriers, excipients, and diluents that may be included in the composition of the present invention may be unnatural carriers, but are not limited thereto.

The pharmaceutical composition of the present invention can be formulated and used in the form of oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, and aerosols, external preparations, suppositories, or sterile injectable solutions according to conventional methods. . In detail, it can be prepared using commonly used diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrants, and surfactants. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and these solid preparations are made by adding at least one excipient to the compound, such as starch, calcium carbonate, sucrose, lactose, gelatin, etc. It can be prepared by mixing. Additionally, in addition to simple excipients, lubricants such as magnesium stearate and talc may also be used. Liquid preparations for oral administration include suspensions, oral solutions, emulsions, and syrups. In addition to the commonly used simple diluents such as water and liquid paraffin, they contain various excipients such as wetting agents, sweeteners, fragrances, and preservatives. You can. Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized preparations, and suppositories. Non-aqueous solvents and suspensions include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate. As a base for suppositories, Withepsol, Macrogol, Tween 61, cacao, laurin, glycerogelatin, etc. can be used. Regarding the specific formulation of pharmaceutical compositions, it is known in the art, and references can be made to, for example, Remington's Pharmaceutical Sciences (19th ed., 1995). The above documents are considered part of this specification.

The pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount. The pharmaceutically effective amount refers to an amount that is sufficient to treat the disease at a reasonable benefit/risk ratio applicable to medical treatment and does not cause side effects. The effective dose level refers to the patient's health status, type and severity of the disease, It can be determined based on factors including the activity of the drug, sensitivity to the drug, method of administration, time of administration, route of administration and excretion rate, duration of treatment, drugs combined or used simultaneously, and other factors well known in the medical field. The dosage and frequency of administration do not limit the scope of the present invention in any way.

The pharmaceutical composition of the present invention can be administered to mammals such as rats, dogs, cats, cows, horses, pigs, and humans through various routes, and humans may be preferable. All modes of administration are contemplated and may include, but are not limited to, oral, intravenous, intramuscular or subcutaneous injection.

In another aspect for achieving the above object, the present invention provides a quasi-drug composition for preventing or treating inflammation or skin itching, comprising an extract of Sikbangpung as an active ingredient. “Sikbangpung”, “extract”, “active ingredient”, “inflammation”, “skin itching”, “prevention” and “treatment” of the present invention are as described above.

The term "quasi-drug" as used in the present invention refers to articles used for the purpose of diagnosing, treating, alleviating, treating, or preventing diseases in humans or animals that are not instruments, machines, or devices, and that have pharmacological effects on the structure and function of humans or animals. Among the products used for the purpose of influencing, it refers to products excluding those that are not instruments, machines, or devices. One specific example may include preparations for internal use, but is not limited thereto, and the formulation method, dosage, and use method of quasi-drugs , components, etc. can be appropriately selected from conventional techniques known in the technical field.

In addition to the above ingredients, the quasi-drug composition of the present invention may further include pharmaceutically acceptable carriers, excipients, or diluents as needed. The pharmaceutically acceptable carrier, excipient, or diluent is not limited as long as it does not impair the effect of the present invention, and includes, for example, fillers, extenders, binders, wetting agents, disintegrants, surfactants, lubricants, sweeteners, fragrances, preservatives, etc. It can be included.

In another aspect for achieving the above object, the present invention includes the steps of (a) adding a solvent to Sikbangpung to prepare a mixture; and (b) extracting the mixture of step (a) by subjecting it to ultrasonic waves. “Sikbangpung” and “extract” of the present invention are as described above.

The step of preparing a mixture by adding a solvent to the windshield of the present invention can be performed by mixing 30 to 50 times the solvent into the windshield, preferably 40 times the amount, but is not limited thereto.

The solvent is not particularly limited, and any solvent known in the art can be used. Non-limiting examples of the solvent include water; Lower alcohols having 1 to 4 carbon atoms such as methanol, ethanol, propanol, isopropanol, butanol, propyl alcohol, and butyl alcohol; Polyhydric alcohols such as glycerin, butylene glycol, and propylene glycol; Hydrocarbon solvents such as methyl acetate, ethyl acetate, acetone, benzene, hexane, diethyl ether, and dichloromethane;　Or a mixture thereof can be used. Specifically, the solvent may be ethanol.

The step of extracting the mixture of the present invention by treating it with ultrasonic waves can be performed three times at 20 to 60 degrees Celsius, preferably 40 Khz at 25 to 50 degrees Celsius, preferably at 35°C for 30 minutes to 3 hours, preferably for 1 hour. It is not limited.

The extraction is not particularly limited and can be extracted according to methods commonly used in the art. In the present invention, the ultrasonic extraction may be performed alone or in combination with two or more methods such as hot water extraction, cold needle extraction, solvent extraction, steam distillation, elution, compression, filtration, and reflux extraction.

The composition of the present invention contains as an active ingredient a natural product, P. fern extract, is non-toxic, and suppresses inflammatory responses by inhibiting nitric oxide production or COX-2 expression and increasing HO-1 (heme oxygenase-1) expression. In addition, it has excellent effects in preventing, improving, or treating itching by suppressing the production of histamine and IL-31 cytokines, which are itch-causing factors, and by suppressing the production of TNF-α and IL-6.

Figure 1 shows the results of confirming the cytotoxicity of the PJRE extract of the present invention in RAW264.7 cells.
Figure 2 shows the results of confirming the cytotoxicity of the PJRE extract of the present invention in HMC-1 cells.
Figure 3 shows the nitric oxide inhibitory effect of the PJRE extract of the present invention increased by LPS treatment.
Figure 4 shows the effect of the PJRE extract of the present invention on reducing COX-2 expression increased by LPS treatment.
Figure 5 shows the effect of reducing the movement of NF-kB and STAT1 into the nucleus by treatment with the PJRE extract of the present invention.
Figure 6 shows the effect of the PJRE extract of the present invention on increasing HO-1 expression, which was reduced by LPS treatment.
Figure 7 shows the effect of increasing the movement of NRF2 into the nucleus by treatment with the PJRE extract of the present invention.
Figure 8 shows the effect of the PJRE extract of the present invention on suppressing histamine production increased by treatment with allergic reaction inducers.
Figure 9 shows the inhibitory effect of the PJRE extract of the present invention on IL-31 production increased by treatment with allergic reaction inducers.
Figure 10 shows the inhibitory effect of the PJRE extract of the present invention on TNF-α production increased by treatment with an allergic reaction inducer.
Figure 11 shows the inhibitory effect of the PJRE extract of the present invention on IL-8 production increased by treatment with an allergic reaction inducer.
Figure 12 shows the effect of the PJRE extract of the present invention on reducing the number of scratches in mice treated with an itch-causing substance.
Figure 13 shows the results of microscopic observation of changes in mouse skin tissue following treatment with the PJRE extract of the present invention.
Figure 14 shows the effect of the PJRE extract of the present invention on increasing mast cells, which was reduced by treatment with itching-causing substances.

Hereinafter, the configuration and effects of the present invention will be described in more detail through examples. These examples are only for illustrating the present invention, and the scope of the present invention is not limited thereto.

Example 1. Preparation of Sikbangpung extract

The root used in this experiment was the root of the perilla plant, purchased from Geumodo, Yeosu-si, Jeollanam-do.

After mixing 400 mL of ethanol with 10 g of Sikbangpung, the mixture was extracted three times with 40Khz ultrasound for 1 hour at 35°C. Afterwards, the ethanol extract of Sikbangpung, which was concentrated under reduced pressure and freeze-dried, was used in the experiment.

Experimental Example 1. Confirmation of cytotoxic effect of Sikbangpung extract

A cytotoxicity evaluation was performed to determine whether the extract of the present invention was toxic.

The cells used were mouse-derived macrophage cell lines RAW264.7 cells and HMC-1 cells purchased from ATCC (American Type Culture Collection). The cells were cultured at 37°C and 5% CO ₂ using DMEM (Dulbecco's modified eagle medium) supplemented with 10% FBS (fetal bovine serum), 100 units/mL penicillin, and 100 μg/mL streptomycin.

RAW 274.7 cells and HMC-1 cells were treated with extracts of Siberia falciparum at concentrations of 12.5, 25, 50, and 100 μg/mL and cultured for 24 hours, followed by 10 μl of WST-1 (water-soluble tetrazolium salts-1) solution. was added and incubated again for 4 hours, and the absorbance was measured at 450 nm. Relative cell viability (% of control) was calculated through comparison with the control group.

As a result, as shown in Figures 1 and 2, it was confirmed that the Sikbangpung extract of the present invention had no cytotoxicity.

Experimental Example 2. Confirmation of nitric oxide production, COX-2 expression, and nuclear movement of transcription factors NF-kB and STAT1 by treatment with P. spp.

In order to confirm the anti-inflammatory effect of the extract of Siberian fragrant root, a test was performed to measure the production of nitric oxide (NO), an inflammatory factor.

Specifically, RAW264.7 cells were dispensed into a 96-well plate at a final concentration of 2×10 ⁵ cells/ml and then cultured for 24 hours at 37°C and 5% CO ₂ conditions. The cultured cells were pretreated with P. falciparum extract (25, 50, and 100 μg/mL) for 1 hour, then treated with LPS (1 μg/mL) and cultured for 16 hours.

100 ㎕ of cell culture and 100 ㎕ of Greek reagent were mixed and reacted at room temperature for 15 minutes. Absorbance was measured at 540 nm using a microplate reader, and a standard curve was created with sodium nitrate to calculate the amount of NO production. Calculated.

As a result, it was confirmed that when the Sikbangpung extract was treated as shown in Figure 3, the production of nitric oxide, which was increased by LPS, decreased in a concentration-dependent manner.

In addition, Western blot analysis was performed to confirm the expression of the inflammatory factor COX-2 and the movement of NF-kB and STAT1 into the nucleus.

Specifically, RAW264.7 cells were dispensed into a 96-well plate at a final concentration of 2×10 ⁵ cells/ml and then cultured for 24 hours at 37°C and 5% CO ₂ conditions. The cultured cells were pretreated with P. falciparum extract (25, 50, and 100 μg/mL) for 1 hour, then treated with LPS (1 μg/mL) and cultured for 16 hours.

Afterwards, the cells were washed by centrifugation twice with PBS (phosphate-buffered saline) and then treated with RIPA buffer (Thermo scientific, USA) to separate the cell proteins. Western blot was performed on the separated proteins to determine the level of COX-2 expression. analyzed. In addition, to confirm the movement of transcription factors NF-kB and STAT1 into the nucleus, cytoplasmic and nuclear proteins were separated and Western blot was performed to analyze the levels of NF-kB and STAT1.

As a result, it was confirmed that the expression of COX-2, which was increased by LPS, was significantly reduced when treated with the extract of Siberian spp. (FIG. 4). In addition, it was confirmed that the intranuclear movement of the transcription factors NF-kB and STAT1 was significantly reduced when treated with Sikbangpung extract (Figure 5).

Experimental Example 3. Confirmation of HO-1 expression and NRF2 intranuclear movement by treatment with Sikbangpung extract

In order to confirm the anti-inflammatory effect of the extract of Siberian fragrant root, Western blot analysis was performed to confirm the expression of the inflammatory factor HO-1 (heme oxygenase 1) and the movement of NRF2 into the nucleus.

Specifically, RAW264.7 cells were dispensed into a 96-well plate at a final concentration of 2×10 ⁵ cells/ml and then cultured for 24 hours at 37°C and 5% CO ₂ conditions. The cultured cells were pretreated with P. falciparum extract (25, 50, and 100 μg/mL) for 1 hour, then treated with LPS (1 μg/mL) and cultured for 16 hours.

Afterwards, the cells were washed by centrifugation twice with PBS (phosphate-buffered saline) and then treated with RIPA buffer (Thermo scientific, USA) to separate the cell proteins. Western blot was performed on the isolated proteins to determine the HO-1 expression level. analyzed. In addition, to confirm the movement of the transcription factor NRF2 into the nucleus, cytoplasmic and nuclear proteins were separated and Western blot was performed to analyze the level of NRF2.

As a result, it was confirmed that when treated with the extract of Siberia falciparum, the expression level of HO-1 increased in a concentration-dependent manner (FIG. 6). In addition, it was confirmed that the movement of the transcription factor NRF2 into the nucleus was significantly increased when treated with the extract of Sikbangpung (FIG. 7).

Experimental Example 4. Confirmation of the effect of inhibiting the production of itching and inflammatory factors by treatment with Sikbangpung extract

In order to confirm the effect of the extract of Siberian fir extract on suppressing skin itching, the inhibition of production of histamine and IL-31, which are itch-causing factors, and the production of inflammatory cytokines (TNF-α and IL-8) were measured.

HMC-1 cells were dispensed into a 96-well plate at a final concentration of 5×10 ⁵ cells/ml and cultured for 24 hours at 37°C and 5% CO ₂ conditions. Cultured cells were treated with Phorbol 12-myristate 13-acetate (PMA) and calcium ionophore A23187 (Sigma-Aldrich, St. Louis, Mo, USA) and 12 hours later, histamine, IL-31, TNF-α, and IL-8 from the cell supernatant were quantified using ELISA KIT.

As a result, it was confirmed that the production of histamine and IL-31 was suppressed and that TNF-α and IL-8 production was also suppressed when treated with the extract of Siberia fragrant root (FIGS. 8 to 11).

Experimental Example 5. Confirmation of itching inhibition effect by Sikbangpung extract treatment

An animal experiment was performed to confirm the itch-suppressing effect of the Sikbangpung extract. Experimental mice were treated according to the egg mass method: normal group (5 mice), C48/80 (Compound 48/80: Sigma-Aldrich, Louis, MO, USA) treated control group (5 mice), C48/80 + Sikbangpung extract ( 100 μg/mL) treatment group (5 animals), C48/80 + Sikbangpung extract (200 μg/mL) treatment group (5 animals), and C48/80 + prednisolone (10 mg/kg) treatment group (5 animals). Designed.

To induce itching and measure scratching behavior, one experimental mouse was placed in a transparent acrylic cage (20 × 26 × 13 cm), and left in the same experimental environment for 30 minutes to stabilize, and then the control group was orally administered saline solution. Afterwards, 100 μL of C48/80, an itch-inducing substance, was subcutaneously injected between both shoulders of the mouse, followed by Mihara's method and recorded for 60 minutes using a micro-camera (ONCCTV, Seoul, Korea), and itching was recorded with the hind paw. The number of times scratching the area where the triggering substance was injected was counted and evaluated in a double-blind method.

As a result, the number of scratches in mice treated only with C48/80 increased sharply, while the number of scratches in mice treated with falciparum extract significantly decreased (FIG. 12).

In addition, H&E stain (Hematoxylin & Eosin) and Skin tissue was stained with toluidine blue and observed under a microscope (Figure 13).

As a result, in the case of mice treated with C48/80, it was confirmed that the infiltration of inflammatory cells, an increase in mast cells, and degranulation were increased compared to the normal control group, while in the case of mice treated with the extract of Sikbanginae, the infiltration of inflammatory cells was confirmed. , it was confirmed that mast cells increased and degranulation decreased (Figure 14).

Although the present invention has been described in detail above, the scope of the present invention is not limited thereto, and it is known in the art that various modifications and variations are possible without departing from the technical spirit of the present invention as set forth in the claims. It will be self-evident to those with knowledge.

Claims (12)

A cosmetic composition for preventing or improving inflammation or skin itchiness, comprising extract of Siberian fragrant root as an active ingredient. According to paragraph 1,
A cosmetic composition wherein the extract of Sikbangpung suppresses the production of nitric oxide or suppresses the expression of COX-2. According to paragraph 1,
A cosmetic composition wherein the extract of Sikbangpung increases the expression of HO-1. According to paragraph 1,
A cosmetic composition wherein the extract of Sikbangpung suppresses the production of TNF-α or IL-6. According to paragraph 1,
The cosmetic composition, wherein the inflammation is any one selected from atopic dermatitis, allergic dermatitis, urticaria, and contact dermatitis. According to paragraph 1,
A cosmetic composition, wherein the skin itching is caused by one or more dermatitis selected from atopic dermatitis, allergic dermatitis, urticaria, and contact dermatitis. According to paragraph 1,
A cosmetic composition wherein the Sikbangpung extract inhibits the production of histamine or IL-31. A food composition for preventing or improving inflammation or skin itchiness, comprising extract of Siberian fragrant root as an active ingredient. A feed composition for preventing or improving inflammation or skin itchiness, comprising extract of Siberian fragrant root as an active ingredient. A pharmaceutical composition for preventing or treating inflammation or itching of the skin, comprising extract of Siberian fragrant root as an active ingredient. A quasi-drug composition for preventing or treating inflammation or itching of the skin, comprising extract of Siberian fragrant root as an active ingredient. Method for preparing Sikbangpung extract comprising the following steps:
(a) preparing a mixture by adding a solvent to Sikbangpung; and
(b) extracting the mixture of step (a) by subjecting it to ultrasonic waves.